nach oben

European Journal of Epidemiology

Erschienen in:

01.07.2009 | CARDIOVASCULAR DISEASE

N-terminal pro B-type natriuretic peptide as prognostic marker for mortality in coronary patients without clinically manifest heart failure

verfasst von: Otto Mayer Jr., Jaroslav Šimon, Markéta Plášková, Renata Cífková, Ladislav Trefil

Erschienen in: European Journal of Epidemiology | Ausgabe 7/2009

Einloggen, um Zugang zu erhalten

Abstract

Brain natriuretic peptide (BNP) and its inactive N-terminal fragment (NT-proBNP) are strong prognostic markers in patients with manifest heart failure and acute coronary syndromes. We aimed to establish the association between NT-proBNP and all-cause mortality in patients with stable chronic coronary heart disease. Three-hundred-eighty-five patients, 6–24 months after acute coronary syndrome or coronary revascularisation, but without history or symptoms of chronic heart failure, were included into the cohort study. The NT-proBNP was measured at baseline and all-cause mortality was ascertained after more than 6 years of follow-up. Patients with NT-proBNP above 862 pmol/l (i.e. in top quintile) showed significantly higher mortality rates, than patients with lower NT-proBNP; the adjusted odds ratio (and 95% confidence intervals) for all-cause death was in patients with NT-proBNP >862 pmol/l 3.26 (1.40–7.62). In conclusion, the asymptomatic elevation of NT-proBNP provides prognostic information also in stable coronary patients not yet manifesting any symptoms of heart failure.

Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321–8. doi:10.1056/NEJM199807303390507.PubMedCrossRef

Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail. 2004;6:257–60. doi:10.1016/j.ejheart.2003.12.015.PubMedCrossRef

Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J. 2003;17:1105–7.PubMed

Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J. 2003;24:1735–43. doi:10.1016/j.ehj.2003.07.005.PubMedCrossRef

Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the carvedilol prospective randomized cumulative survival (COPERNICUS) trial. Circulation. 2004;110:1780–6. doi:10.1161/01.CIR.0000143059.68996.A7.PubMedCrossRef

James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a global utilization of strategies to open occluded arteries (GUSTO)-IV substudy. Circulation. 2003;108:275–81. doi:10.1161/01.CIR.0000079170.10579.DC.PubMedCrossRef

de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014–21. doi:10.1056/NEJMoa011053.PubMedCrossRef

Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, et al. Australia-New Zealand Heart Failure Group. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol. 2001;37:1781–7. doi:10.1016/S0735-1097(01)01269-4.PubMedCrossRef

Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005;352:666–75. doi:10.1056/NEJMoa042330.PubMedCrossRef

10.

Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655–63. doi:10.1056/NEJMoa031994.PubMedCrossRef

11.

EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II. Eur Heart J. 2001;22:554–72. doi:10.1053/euhj.2001.2610.CrossRef

12.

Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. Clin Chem. 2003;49:976–9. doi:10.1373/49.6.976.PubMedCrossRef

13.

Omland T, Persson A, Ng L, O’Brien R, Karlsson T, Herlitz J, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002;106:2913–8. doi:10.1161/01.CIR.0000041661.63285.AE.PubMedCrossRef

14.

Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart. 2004;90:297–303. doi:10.1136/hrt.2003.026021.PubMedCrossRef

15.

Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. INTERHEART Study investigators: effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52. doi:10.1016/S0140-6736(04)17018-9.PubMedCrossRef

16.

Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, et al. HOPE study investigators. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the heart outcomes prevention evaluation (HOPE) study. Circulation. 2006;114:201–8. doi:10.1161/CIRCULATIONAHA.105.590927.PubMedCrossRef

17.

De Bacquer D, De Backer G, Ostor E, Simon J, Pyorala K. EUROASPIRE I Study Group.Predictive value of classical risk factors and their control in coronary patients: a follow-up of the EUROASPIRE I cohort. Eur J Cardiovasc Prev Rehabil. 2003;10:289–95. doi:10.1097/00149831-200308000-00012.PubMedCrossRef

18.

Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. REACH Registry Investigators International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180–9. doi:10.1001/jama.295.2.180.PubMedCrossRef

19.

Miller WL, Skouri HN. Chronic systolic heart failure, guideline-directed medical therapy, and systemic hypotension-less pressure but maybe more risk (does this clinical scenario need more discussion?). J Card Fail. 2009;15:101–7. doi:10.1016/j.cardfail.2008.07.228.PubMedCrossRef

Titel: N-terminal pro B-type natriuretic peptide as prognostic marker for mortality in coronary patients without clinically manifest heart failure
verfasst von: Otto Mayer Jr.
Jaroslav Šimon
Markéta Plášková
Renata Cífková
Ladislav Trefil
Publikationsdatum: 01.07.2009
Verlag: Springer Netherlands
Erschienen in: European Journal of Epidemiology / Ausgabe 7/2009
Print ISSN: 0393-2990
Elektronische ISSN: 1573-7284
DOI: https://doi.org/10.1007/s10654-009-9339-6

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2009

Lay perceptions of the pandemic influenza threat

Association of low total testosterone levels and prevalent carotid plaques: result of the study of health in Pomerania

Does mortality of the aged increase with the number of falls? Results from a nine-year follow-up study

Sex differences in the association between infant feeding and blood cholesterol in later life: the Newcastle thousand families cohort study at age 49–51 years

The impact of unmeasured baseline effect modification on estimates from an inverse probability of treatment weighted logistic model

A graphical study of tuberculosis incidence and trends in the WHO’s European region (1980–2006)